Biaryl guanidine inhibitors of in vitro HCV-IRES activity.
A structure-activity relationship analysis was carried out on a high-throughput small molecule screening lead for HCV-IRES translation inhibition. The study led to the identification of a guanidine-based structure with low microM inhibitory activity.
Jefferson
Elizabeth A
EA
Ibis Therapeutics, A Division of Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA. ejeffers@isiph.com
Seth
Punit P
PP
Robinson
Dale E
DE
Winter
Dana K
DK
Miyaji
Alycia
A
Osgood
Stephen A
SA
Swayze
Eric E
EE
Risen
Lisa M
LM
D000998:Antiviral Agents / Q000737:chemistry* / Q000494:pharmacology; D016208:Databases, Factual; D006146:Guanidines / Q000737:chemistry*; D016174:Hepacivirus / Q000235:genetics* / Q000378:metabolism; D014176:Protein Biosynthesis / Q000187:drug effects*; D012270:Ribosomes / Q000187:drug effects / Q000235:genetics; D013329:Structure-Activity Relationship; D014158:Transcription, Genetic / Q000187:drug effects; D014764:Viral Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis
D000998:Antiviral Agents; D006146:Guanidines; D014764:Viral Proteins